LRRC3-DT

Across TCGA pan-cancer cohorts, LRRC3-DT RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated LRRC3-DT data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LRRC3-DT RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRRC3-DT expression acts as an unfavorable survival marker, although some lineages such as LIHC and BLCA show a favorable association.

CHOL, KIRC, and LIHC are the cancer types where LRRC3-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	II,III,IV	0.100	0.517	.003	67	view →
KIRC	DFS	Median	All	0.490	0.691	<.001	64	view →
LIHC	OS	Tertile	All	0.780	0.549	<.001	63	view →
MESO	DFS	Tertile	II,III,IV	0.252	0.486	.002	60	view →
KIRP	DFS	Median	II,III,IV	0.233	0.913	.001	53	view →
UCEC	OS	Median	All	0.454	0.782	.001	52	view →
BLCA	OS	Tertile	III,IV	0.782	0.597	.001	51	view →
BRCA	OS	Median	IV	0.322	0.765	.002	27	view →
ACC	DFS	Median	IV	0.453	0.108	.019	21	view →
UVM	DFS	Tertile	III,IV	0.158	0.727	.015	18	view →
DLBC	DFS	Tertile	II,III,IV	0.564	0.956	.037	18	view →
LUSC	OS	Tertile	III,IV	0.397	0.859	.010	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

LRRC3-DT–CHOL (DFS)

Open the CHOL breakdown →